The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElixirr International Regulatory News (ELIX)

Share Price Information for Elixirr International (ELIX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 570.00
Bid: 560.00
Ask: 580.00
Change: 0.00 (0.00%)
Spread: 20.00 (3.571%)
Open: 570.00
High: 570.00
Low: 570.00
Prev. Close: 570.00
ELIX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Dealing

26 Jan 2024 07:00

RNS Number : 9747A
Elixirr International PLC
26 January 2024
 

26 January 2024

 

Elixirr International plc

 

("Elixirr", the "Company" or the "Group")

 

Director Dealing

Elixirr International plc (AIM:ELIX), an established, global award-winning challenger consultancy, announces that on 25 January 2024 Charlotte Stranner, Non-Executive Director of the Company, sold 69,566 ordinary shares of 0.005p each in the Company ("Ordinary Shares") at a price of 575p per Ordinary Share.

Following the sale, Charlotte Stranner's beneficial holding is 300,439 Ordinary Shares representing 0.64 per cent. of the issued share capital of the Company.

For further information please contact:

Elixirr International plc

Stephen Newton, CEO

Graham Busby, CFO

 

 

 

 

Public and Investor Relations contacts:

investor-relations@elixirr.com 

 

Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)

Stephen Keys, Charlie Beeson (Corporate Finance),

Sunila De Silva (ECM)

 

Investec Bank plc (Joint Broker)

Carlton Nelson, Henry Reast (Corporate Broking)

 

 

 

 

 

+44 (0) 20 7220 0500

 

 

 

+44 (0) 20 7597 4000

 

About Elixirr International plc

Elixirr is an established global award-winning management consultancy, challenging the larger consultancies by delivering innovative and bespoke solutions to a repeat, globally-recognised client base.

Elixirr was founded in 2009, by Stephen Newton, Graham Busby, Ian Ferguson, Andy Curtis and Mark Goodyear, experienced business advisors who identified a market opportunity to provide bespoke, personal services as a 'challenger' to the traditional consultancy businesses in the market. Elixirr guides its clients to overcome challenges such as: future-proofing against technological disruption; development and roll-out of innovative new propositions, products and services; incubating new businesses; navigating a more complex and multinational regulatory environment; and project management and implementation of major change programmes.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Charlotte Stranner

2

Reason for the notification

a)

Position/status

Non-Executive Director

b) 

Initial notification /Amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Elixirr International plc

b)

LEI

213800MKY7OHMVAKW681

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument 

Identification code

Ordinary shares of 0.005p each ("Ordinary Shares")

 

GB00BLPHTX84

b)

Nature of the transaction

Sale of Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

575p

 

 

69,566

 

d)

Aggregated information

- Aggregated volume

- Price

n/a

e)

Date of the transaction

25 January 2024

f)

Place of the transaction

AIMX

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSEWFWIELSELF
12
Date   Source Headline
24th Apr 20247:00 amRNSGrant of Share Options
22nd Apr 20247:00 amRNSFinal Results
8th Apr 20247:00 amRNSNotice of FY 23 Results and Investor Presentation
26th Jan 20247:00 amRNSDirector Dealing
8th Jan 20247:00 amRNSTrading Update and Change to Dividend Policy
11th Dec 20237:00 amRNSAcquisition of Insigniam LLC and Insigniam SAS
18th Sep 20237:00 amRNSInterim Results
18th Sep 20237:00 amRNSAcquisition of Responsum, Inc.
13th Jun 202310:45 amRNSResult of AGM
24th May 20231:31 pmRNSHolding(s) in Company
19th May 20237:00 amRNSPosting of Annual Report and Accounts
10th May 20233:00 pmRNSDirector/PCA Dealings
26th Apr 20237:00 amRNSGrant of Share Options
12th Apr 20237:00 amRNSAppointment of Joint Corporate Broker
4th Apr 20233:00 pmRNSDirector Dealing
3rd Apr 20239:15 amRNSDirector Dealing
3rd Apr 20237:00 amRNSFinal Results
28th Mar 20237:00 amRNSInvestor Presentation
27th Feb 20239:05 amRNSSecond Price Monitoring Extn
27th Feb 20239:00 amRNSPrice Monitoring Extension
27th Feb 20237:00 amRNSTrading Update
24th Feb 20232:05 pmRNSSecond Price Monitoring Extn
24th Feb 20232:00 pmRNSPrice Monitoring Extension
24th Feb 202311:05 amRNSSecond Price Monitoring Extn
24th Feb 202311:00 amRNSPrice Monitoring Extension
29th Nov 20221:15 pmRNSInvestor Presentation
11th Nov 20227:00 amRNSDirector Dealing
20th Oct 20227:00 amRNSPCA Dealing
6th Oct 20227:00 amRNSPurchase of Shares by Employee Benefit Trust
20th Sep 20227:00 amRNSInterim Results
12th Sep 20227:00 amRNSNotice of Interim Results
29th Jul 20224:41 pmRNSSecond Price Monitoring Extn
29th Jul 20224:35 pmRNSPrice Monitoring Extension
11th Jul 20221:45 pmRNSPDMR/PCA Dealing
7th Jul 202211:15 amRNSPCA Dealing
13th Jun 20221:00 pmRNSResult of AGM
19th May 20227:00 amRNSPosting of Annual Report & Accounts
29th Apr 20224:07 pmRNSResult of Secondary Placing
28th Apr 20224:06 pmRNSProposed Secondary Placing
8th Apr 20224:15 pmRNSDirector/PDMR Shareholding
4th Apr 20227:00 amRNSFinal Results
18th Mar 20227:00 amRNSAcquisition of iOLAP and FY2022 Earnings
1st Feb 20227:00 amRNSTrading Update
30th Nov 20217:00 amRNSDirector/PDMR Shareholding
13th Oct 202111:41 amRNSResult of Secondary Placing
13th Oct 20217:00 amRNSProposed Secondary Placing
27th Sep 20217:00 amRNSInterim Results
17th Jun 20218:13 amRNSDirector/PDMR Shareholding
16th Jun 202112:21 pmRNSResult of AGM
16th Jun 20217:00 amRNSAGM Statement
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.